Trinomab Biotech, a Chinese clinical-stage biopharmaceutical firm with operations globally, announced on Tuesday the completion of its pre-IPO financing at about 750 million yuan ($104.4 million) to advance its product pipeline.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
